
    
      This trial will be split into two parts. The purpose of Part 1 will be to confirm dose and
      target patient population and Part 2 will be expansion of the dose and patient population
      selected in Part 1. For eligible patients, there will be an optional extension dosing
      following the completion of Part 1 or Part 2 of the trial.

      Obtaining of informed consent and screening may be performed up to 28 days prior to
      enrollment. Each patient will be able to receive his specified regimen for 3 consecutive
      cycles. Each cycle consists of 28 days (approximately 1 mo.). End of Cycle 3 visit
      assessments will be used to determine outcome and dosing may continue up to an additional 2
      weeks until the results of all assessments are obtained. Eligible patients may continue
      treatment in an optional extension period following the completion of the primary parts of
      this trial.
    
  